J.D. University of San Diego (2010) B.S. in Biology and Political Science, Arizona State University (2007)
La Canada Flintridge Women's Golf Association
Ms. Daughtrey focuses her practice on intellectual property litigation and counseling, with a focus in the pharmaceutical space including biologics and biosimilars. Ms. Daughtrey has experience representing companies in all stages of patent litigation from pre- suit investigation through trial and appeal. She also advises clients on patent-related due diligence. Ms. Daughtrey is also a contributing editor on Goodwin Procter's Big Molecule Watch (https://www.bigmoleculewatch.com/).
Representative matters include:
•Genzyme Corporation, et al. v. Teva Pharmaceuticals USA, Inc., et al., No. 1:13-cv-01506 (D. Del.): Representing Teva in an ongoing patent infringement litigation filed by Genzyme under the Hatch-Waxman Act in response to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of Genzyme’s stem cell mobilizing agent, Mozobil® (plerixafor).
•Senju Pharmaceutical Co., Ltd., et al., v, Lupin Ltd., et al., No. 1:14-cv-6893 (D.N.J.):Representing Lupin in an ongoing patent infringement litigation filed by Senju under the Hatch-Waxman Act in response to Lupin’s filing of an abbreviated new drug application seeking approval to market a generic version of Senju’s Prolensa® (bromfenac ophthalmic solution) medication.
•Prometheus Laboratories Inc. v. Roxane Laboratories, Inc., et al., No. 2:11-cv-01241 (D.N.J.): Representing Roxane in a patent infringement litigation filed by Prometheus in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Prometheus’s IBS treatment drug, Lotronex® (alosetron hydrochloride). After a bench trial, the District Court found in favor of Roxane that Prometheus’s patent was invalid.